Why Do Medical Guidelines Disagree—and What Should Patients Do?

Expert panels may interpret the same evidence differently
Recommendations reflect judgments about benefits, risks, and uncertainty
Patients still need an individualized medical decision

Patients often expect medical guidelines to provide one clear answer. It can therefore be unsettling to discover that respected professional organizations recommend different tests, treatment thresholds, medication durations, or follow-up plans for the same condition.

Conflicting guidelines do not necessarily mean that one organization understands the science and another does not. The groups may have reviewed overlapping evidence but reached different conclusions about its quality, the importance of particular outcomes, the acceptable risk of treatment, or the consequences of delaying care.

Guidelines are valuable tools, but they are not simply collections of medical facts. They translate evidence into recommendations. That translation requires judgment—and judgment becomes particularly important when the evidence is limited, indirect, inconsistent, or unlikely to apply equally to every patient.

What is a clinical practice guideline?

A clinical practice guideline is a set of recommendations intended to help clinicians and patients make decisions about diagnosis, treatment, screening, prevention, or follow-up. A trustworthy guideline should be based on a systematic review of the evidence and developed through a transparent process.

Guideline panels may include physicians, researchers, methodologists, other healthcare professionals, and patient representatives. Panel members consider clinical trials, observational studies, diagnostic research, adverse effects, patient-important outcomes, and limitations in the available evidence.

The final recommendation does not come directly from a study. The panel must decide how the evidence should influence clinical practice.

Why can guidelines based on the same evidence reach different conclusions?

Evidence describes what researchers observed in selected populations under specific conditions. A guideline panel must then decide how confidently those findings can be applied to patients outside the study and whether the expected benefit justifies the potential harms and burdens.

Different panels may answer those questions differently. They may disagree about:

• Which studies should be included
• Whether a study population resembles patients seen in ordinary practice
• How much weight to give randomized trials compared with observational evidence
• Whether a measured outcome is meaningful to patients
• How serious or reversible the treatment risks are
• Whether the consequences of undertreatment are greater than those of overtreatment
• How much uncertainty is acceptable before making a recommendation
• How strongly patient preferences should influence the decision

The disagreement may therefore occur even when neither panel has made an obvious factual error.

Does stronger evidence always produce the same recommendation?

High-certainty evidence can reduce disagreement, but it may not eliminate it. A well-conducted trial may establish that a treatment changes a particular outcome while leaving other questions unresolved.

For example, a study may show that treatment produces a modest average benefit but also increases adverse effects. One guideline panel may consider that benefit sufficient to recommend treatment for most eligible patients. Another may conclude that the benefit is too small to justify routine treatment and recommend individualized decision-making instead.

The panels are not necessarily disputing the trial result. They may be assigning different importance to the benefit, adverse effects, treatment burden, cost, or patient preferences.

What happens when the evidence is limited?

Guideline disagreement becomes more likely when studies are small, enroll highly selected patients, use different definitions, measure different outcomes, or provide limited long-term follow-up. Evidence may also be indirect because the exact patient population, diagnostic strategy, dose, or treatment duration has not been adequately studied.

A panel can respond to limited evidence in several ways. It may recommend against an intervention until stronger evidence becomes available. It may issue a conditional recommendation for selected patients. It may allow several reasonable options. It may also conclude that the decision should depend heavily on the patient’s circumstances and preferences.

Absence of strong evidence of benefit is not always the same as evidence that an intervention cannot help. At the same time, uncertainty does not establish that the intervention is effective or safe. A careful recommendation must acknowledge both limits.

What is the difference between a strong and conditional recommendation?

Many guideline systems distinguish between strong and conditional—or weak—recommendations.

A strong recommendation generally means that the panel believes the desirable consequences clearly outweigh the undesirable consequences for nearly all patients in the defined population. Clinicians should still consider contraindications and individual circumstances, but the recommendation will usually apply broadly.

A conditional recommendation means that different choices may be appropriate for different patients. The evidence may be uncertain, the expected benefits and harms may be closely balanced, or patients may reasonably place different values on the outcomes.

Conditional does not mean unimportant. It means that shared decision-making is especially necessary.

Does a strong recommendation always rest on strong evidence?

Not necessarily. Some guideline frameworks permit strong recommendations based on lower-certainty evidence under limited circumstances—for example, when a potentially catastrophic harm is plausible and an alternative is safer.

This is why patients and clinicians should look beyond the word “recommended.” The guideline should explain both the certainty of the evidence and the strength of the recommendation. Those are related concepts, but they are not identical.

How do benefits and harms influence medical guidelines?

Guideline panels must consider more than whether a treatment can work. They must also consider how much it helps, which outcomes improve, how often adverse effects occur, and whether the expected benefit applies to the patient being treated.

Two panels may view the balance differently. One may be more concerned about medication toxicity, false-positive testing, unnecessary procedures, or overtreatment. Another may place greater weight on the consequences of missing a diagnosis, delaying treatment, or leaving disabling symptoms insufficiently addressed.

These differences are particularly important when both action and inaction carry potential harm. A recommendation focused mainly on avoiding unnecessary treatment may not give the same weight to delayed recovery, disease progression, or loss of function. Conversely, a recommendation focused on preventing undertreatment may accept risks that another panel considers excessive.

Do patient values affect guideline recommendations?

They should. Patients do not always assign the same importance to the same outcomes.

One patient may accept substantial treatment burden for a small possibility of improvement. Another may prioritize avoiding adverse effects. A patient whose symptoms threaten employment or independent living may evaluate uncertainty differently from someone with mild, stable symptoms.

Guideline panels can incorporate published research about patient values and include patient representatives. However, no panel can anticipate every person’s priorities, medical history, responsibilities, access to care, or tolerance for risk.

A guideline can inform a decision, but it cannot make every decision for every patient.

Can conflicts of interest affect guidelines?

Financial and professional conflicts of interest deserve attention because they can influence how evidence is framed or interpreted. Trustworthy guideline development therefore requires disclosure, management of relevant conflicts, transparent methods, and appropriate limits on the roles of members with significant conflicts.

However, a disclosed relationship does not automatically invalidate a recommendation, just as the absence of a disclosed financial relationship does not guarantee an unbiased conclusion. Intellectual commitments, professional experience, institutional priorities, and previous public positions can also shape judgment.

Patients should avoid dismissing an entire guideline solely because one panel member reported a relationship. The more useful questions are whether conflicts were disclosed, how they were managed, whether the evidence review was systematic, and whether the reasoning behind each recommendation is transparent.

Does the date of the guideline matter?

Yes. A guideline may have been methodologically sound when published but become outdated as new tests, treatments, safety findings, or longer-term studies emerge.

Check when the literature search was completed—not only the publication date. Guideline development can take considerable time, so the evidence review may already be several years old when the document appears.

A newer guideline is not automatically better. It may use a less rigorous process or interpret the evidence less carefully. Nevertheless, important evidence published after an older guideline’s search date may justify reconsidering its recommendations.

Why might guidelines not fit an individual patient?

Clinical studies commonly exclude patients with multiple illnesses, unusual presentations, previous treatment failures, advanced age, pregnancy, medication intolerance, or complicated diagnostic histories. As a result, the patients seen in practice may differ substantially from those enrolled in the supporting trials.

A patient may also have more than one condition contributing to the same symptoms. A recommendation developed for an isolated diagnosis may not fully address medication interactions, competing risks, functional limitations, or the effect of another illness.

The physician’s task is not simply to ask, “What does the guideline say?” It is also to ask, “How closely does this patient resemble the population and clinical circumstances addressed by the guideline?”

Why do Lyme disease guidelines disagree?

Lyme disease illustrates how guideline disagreements may involve more than a different reading of a single study. Professional organizations have differed in their assessments of diagnostic uncertainty, prevention after a tick bite, treatment options, persistent manifestations, and the role of patient preferences when evidence is limited.

The International Lyme and Associated Diseases Society guidelines, which I helped author, used the GRADE framework and emphasized individualized decision-making in areas supported by very-low-quality evidence. Guidelines developed by the Infectious Diseases Society of America, American Academy of Neurology, and American College of Rheumatology reached different conclusions on several questions.

Those differences should be discussed accurately. They do not establish that every proposed Lyme treatment is effective, nor do they mean that persistent symptoms should automatically be attributed to ongoing infection. They do show that the relationship between evidence and recommendations may depend on how panels weigh uncertainty, treatment risks, patient preferences, and the consequences of withholding additional care.

Patients should not be expected to settle a complex methodological dispute alone. Their clinicians should explain which recommendation they are following, why it fits the clinical situation, what uncertainties remain, and what will happen if the chosen plan does not help.

What should patients do when medical guidelines disagree?

Begin by confirming that the recommendations truly conflict. Guidelines may address different patient groups, disease stages, test results, or treatment goals. One may apply to screening while another applies to diagnosis. One may discuss initial treatment while another addresses persistent or recurrent symptoms.

Patients can then ask:

• Which guideline are you using, and when was it published?
• Does it directly address my clinical situation?
• How certain is the evidence behind this recommendation?
• Is the recommendation strong or conditional?
• What benefit can I realistically expect?
• What are the risks and burdens of each option?
• What could happen if we wait, monitor, or do nothing?
• Would another guideline support a different reasonable choice?
• How will we determine whether the plan is working?
• What findings would cause us to reconsider the decision?

These questions are more useful than asking which organization is universally correct. The goal is to understand why a particular recommendation should—or should not—apply to the individual patient.

Should patients seek a second opinion?

A second opinion may be helpful when the diagnosis is uncertain, the proposed treatment carries substantial risk, the available options have different long-term consequences, or clinicians interpret the evidence differently.

The second clinician should review the history and evidence independently rather than merely vote for one recommendation. Another opinion is most useful when it clarifies why the recommendations differ and identifies what additional information could change the decision.

Repeated opinions may become less helpful if they produce additional recommendations without resolving the underlying uncertainty. At some point, the patient and clinician may need to choose among reasonable options and establish a clear monitoring plan.

When is individualized care appropriate?

Individualized care does not mean ignoring evidence or choosing any treatment a patient requests. It means applying the best available evidence to the patient’s diagnosis, risks, previous treatment response, goals, preferences, and alternatives.

Departing from a guideline may be reasonable when the patient differs materially from the population addressed, has contraindications, has already failed the recommended approach, or faces circumstances the guideline did not consider. The physician should be able to explain and document that reasoning.

Individualization is especially important when a recommendation is conditional or the evidence is uncertain. It should not be used to disregard a strong, well-supported recommendation without a clinically persuasive reason.

This article is for informational purposes only and is not a substitute for individualized medical advice, diagnosis, or treatment. Do not start, stop, or change treatment solely because professional guidelines disagree. Discuss the evidence and your individual circumstances with a qualified healthcare professional.

Frequently Asked Questions

Why do medical guidelines sometimes contradict each other?

Guidelines may contradict each other because panels include different studies, assess the certainty of evidence differently, prioritize different outcomes, or place different weight on treatment risks, undertreatment, patient preferences, cost, and feasibility.

Does guideline disagreement mean that medical science is unreliable?

No. Disagreement often identifies areas where evidence is incomplete or where reasonable judgments differ. It should prompt a closer examination of the evidence and recommendation rather than rejection of medical science altogether.

Should a doctor always follow the newest guideline?

Not automatically. A newer guideline may include more recent evidence, but its methods, scope, evidence quality, and relevance to the individual patient still matter. The date of the guideline’s literature search should also be reviewed.

Can a doctor reasonably depart from a medical guideline?

Yes. A physician may depart from a guideline when the patient differs from the population addressed, has contraindications, has failed the recommended approach, or has circumstances and preferences that support another reasonable option. The clinical reasoning should be clear and documented.

What should I ask when two guidelines recommend different treatments?

Ask how certain the evidence is, whether each guideline applies to your situation, what benefits and harms are expected, what could happen without treatment, whether the recommendations are strong or conditional, and how your response will be monitored.

Clinical Takeaway

Clinical guidelines organize evidence and can improve consistency of care, but they do not remove the need for judgment. Recommendations may differ because panels assess evidence, benefits, harms, uncertainty, and patient priorities differently.

When guidelines disagree, patients deserve more than an instruction to follow one organization without explanation. The clinician should identify which guidance applies, explain the evidence and uncertainty, consider reasonable alternatives, and establish a plan for monitoring the outcome.

The most useful guideline is not necessarily the one with the most confident wording; it is the one whose evidence, assumptions, and recommendations best fit the patient facing the decision.

Related Articles

Lyme Disease Misdiagnosis: Why the Diagnosis Can Be Missed
Persistent Lyme Disease: Why Symptoms May Continue
Unexplained Symptoms: What Should Happen Next?

References

1. Graham, R., Mancher, M., Miller Wolman, D., Greenfield, S., & Steinberg, E. Clinical practice guidelines we can trust. National Academies Press. 2011.
2. Brignardello-Petersen, R., Carrasco-Labra, A., & Guyatt, G. H. How to interpret and use a clinical practice guideline or recommendation: Users’ guides to the medical literature. JAMA. 2021;326(15):1516–1523.
3. Neumann, I., Brignardello-Petersen, R., Wiercioch, W., et al. The GRADE evidence-to-decision framework: A report of its testing and application in 15 international guideline panels. Implementation Science. 2016;11:93.
4. Zhang, Y., Coello, P. A., Guyatt, G. H., et al. GRADE guidelines: 20. Assessing the certainty of evidence in the importance of outcomes or values and preferences—inconsistency, imprecision, and other domains. Journal of Clinical Epidemiology. 2019;111:83–93.
5. Norris, S. L., Holmer, H. K., Ogden, L. A., & Burda, B. U. Conflict of interest in clinical practice guideline development: A systematic review. PLoS ONE. 2011;6(10):e25153.
6. Cameron, D. J., Johnson, L. B., & Maloney, E. L. Evidence assessments and guideline recommendations in Lyme disease: The clinical management of known tick bites, erythema migrans rashes and persistent disease. Expert Review of Anti-infective Therapy. 2014;12(9):1103–1135.
7. Lantos, P. M., Rumbaugh, J., Bockenstedt, L. K., et al. Clinical practice guidelines by the Infectious Diseases Society of America, American Academy of Neurology, and American College of Rheumatology: 2020 guidelines for the prevention, diagnosis, and treatment of Lyme disease. Neurology. 2021;96(6):262–273.

“`

---

Dr. Daniel Cameron, MD, MPH
Lyme disease clinician with over 30 years of experience and past president of ILADS.

Symptoms • Testing • Coinfections • Recovery • Pediatric • Prevention